Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases.
Identifieur interne : 000001 ( PubMed/Curation ); précédent : 000000; suivant : 000002Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases.
Auteurs : Marie Von Lilienfeld-Toal [Allemagne] ; Jörg Janne Vehreschild [Allemagne] ; Oliver Cornely [Allemagne] ; Livio Pagano [Italie] ; Francesca Compagno [Italie] ; Hans H. Hirsch [Suisse]Source :
- Leukemia [ 1476-5551 ] ; 2020.
Abstract
Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.
DOI: 10.1038/s41375-020-0832-y
PubMed: 32358568
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000001
Links to Exploration step
pubmed:32358568Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases.</title><author><name sortKey="Von Lilienfeld Toal, Marie" sort="Von Lilienfeld Toal, Marie" uniqKey="Von Lilienfeld Toal M" first="Marie" last="Von Lilienfeld-Toal">Marie Von Lilienfeld-Toal</name><affiliation wicri:level="1"><nlm:affiliation>Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany. Marie.von_Lilienfeld-Toal@med.uni-jena.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena</wicri:regionArea></affiliation></author><author><name sortKey="Vehreschild, Jorg Janne" sort="Vehreschild, Jorg Janne" uniqKey="Vehreschild J" first="Jörg Janne" last="Vehreschild">Jörg Janne Vehreschild</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main</wicri:regionArea></affiliation></author><author><name sortKey="Cornely, Oliver" sort="Cornely, Oliver" uniqKey="Cornely O" first="Oliver" last="Cornely">Oliver Cornely</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Pagano, Livio" sort="Pagano, Livio" uniqKey="Pagano L" first="Livio" last="Pagano">Livio Pagano</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Universita Cattolica del Sacro Cuore, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Compagno, Francesca" sort="Compagno, Francesca" uniqKey="Compagno F" first="Francesca" last="Compagno">Francesca Compagno</name><affiliation wicri:level="1"><nlm:affiliation>Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia</wicri:regionArea></affiliation></author><author><name sortKey="Hirsch, Hans H" sort="Hirsch, Hans H" uniqKey="Hirsch H" first="Hans H" last="Hirsch">Hans H. Hirsch</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32358568</idno><idno type="pmid">32358568</idno><idno type="doi">10.1038/s41375-020-0832-y</idno><idno type="wicri:Area/PubMed/Corpus">000001</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000001</idno><idno type="wicri:Area/PubMed/Curation">000001</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000001</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases.</title><author><name sortKey="Von Lilienfeld Toal, Marie" sort="Von Lilienfeld Toal, Marie" uniqKey="Von Lilienfeld Toal M" first="Marie" last="Von Lilienfeld-Toal">Marie Von Lilienfeld-Toal</name><affiliation wicri:level="1"><nlm:affiliation>Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany. Marie.von_Lilienfeld-Toal@med.uni-jena.de.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena</wicri:regionArea></affiliation></author><author><name sortKey="Vehreschild, Jorg Janne" sort="Vehreschild, Jorg Janne" uniqKey="Vehreschild J" first="Jörg Janne" last="Vehreschild">Jörg Janne Vehreschild</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main</wicri:regionArea></affiliation></author><author><name sortKey="Cornely, Oliver" sort="Cornely, Oliver" uniqKey="Cornely O" first="Oliver" last="Cornely">Oliver Cornely</name><affiliation wicri:level="1"><nlm:affiliation>Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne</wicri:regionArea></affiliation></author><author><name sortKey="Pagano, Livio" sort="Pagano, Livio" uniqKey="Pagano L" first="Livio" last="Pagano">Livio Pagano</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Hematology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Universita Cattolica del Sacro Cuore, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Compagno, Francesca" sort="Compagno, Francesca" uniqKey="Compagno F" first="Francesca" last="Compagno">Francesca Compagno</name><affiliation wicri:level="1"><nlm:affiliation>Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia</wicri:regionArea></affiliation></author><author><name sortKey="Hirsch, Hans H" sort="Hirsch, Hans H" uniqKey="Hirsch H" first="Hans H" last="Hirsch">Hans H. Hirsch</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel</wicri:regionArea></affiliation></author></analytic><series><title level="j">Leukemia</title><idno type="eISSN">1476-5551</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32358568</PMID><DateRevised><Year>2020</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5551</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2020</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41375-020-0832-y</ELocationID><Abstract><AbstractText>Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>von Lilienfeld-Toal</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany. Marie.von_Lilienfeld-Toal@med.uni-jena.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leibniz-Institut für Infektionsbiologie und Naturstoff Forschung, Hans-Knöll Institut, Jena, Germany. Marie.von_Lilienfeld-Toal@med.uni-jena.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vehreschild</LastName><ForeName>Jörg Janne</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Hematology/Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornely</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EHA Infectious Diseases Scientific Working Group, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagano</LastName><ForeName>Livio</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Hematology, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Compagno</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EHA Infectious Disease Scientific Working Group</CollectiveName></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Hans H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><InvestigatorList><Investigator ValidYN="Y"><LastName>Pagliuca</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akan</LastName><ForeName>Hamdi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lagrou</LastName><ForeName>Katrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pagano</LastName><ForeName>Livio</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoenigl</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klimko</LastName><ForeName>Nikolai</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cornely</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verweij</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duarte</LastName><ForeName>Rafael</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerli</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bretagne</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Racil</LastName><ForeName>Zdenek</ForeName><Initials>Z</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32358568</ArticleId><ArticleId IdType="doi">10.1038/s41375-020-0832-y</ArticleId><ArticleId IdType="pii">10.1038/s41375-020-0832-y</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000001 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000001 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:32358568
|texte= Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:32358568" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |